CFR Chemaphor Inc.

Chemaphor (TSX VENTURE:CFR) announced today that it has completed its internal
clinical development program of its Oximunol(TM) Chewables, a proprietary
natural health enhancer for dogs. The program included the assessment of product
efficacy through a blinded placebo-controlled field study in dogs, a
determination of mode of action via the conduct of in vitro and in vivo studies,
a determination of product safety in a controlled target animal safety study,
and the confirmation of product palatability, including a comparison with a
standard animal health product positive control. The results of these multiple
studies clearly demonstrated that Oximunol(TM) Chewables are highly palatable
and that in the first pilot clinical trial they significantly improved the coat
quality and reduced shedding. In addition, treated dogs showed a tendency to
increased enjoyment of walks and there were, no adverse effects observed in the
safety study.


With the completion of this milestone, Chemaphor is targeting product
introduction in Canada, the United States and Mexico. Oximunol(TM) Chewables are
in a class of natural nutritional supplements, which is not regulated in Canada
or the USA. In the USA voluntary regulation is through the National Animal
Supplement Council (NASC). Chemaphor is a member of NASC and by complying with
the NASC requirements and standards Oximunol(TM) Chewables will carry the NASC
Quality Seal. Chemaphor will adhere to the same standards in Canada and Mexico.


Dr Paul Dick, CEO of Chemaphor, indicated that "the completion of this
development milestone represents a significant accomplishment which
strategically positions the company to move to commercialization".


About Oximunol(TM) Chewables 

Oximunol(TM) Chewables contain OxC-beta, a proprietary mixture of carotenoid
oxidation products. Oxidized derivatives of carotenoids occur extensively in the
plant world in minute amounts and, as such, are a natural part of the diet.
OxC-beta is obtained via the spontaneous, full oxidation of beta-carotene. Uses
for OxC-beta and other oxidized carotenoid products are protected by patents
owned by Chemaphor in multiple jurisdictions. Additionally, Chemaphor has filed
patent applications directed to products containing OxC-beta and its use for
enhancing and maintaining the wellness of companion animals.


About Chemaphor

Chemaphor is a wellness company that is committed to developing and delivering
natural health enhancer ("NHE") products to humans and animals to assist in
optimizing health and daily quality of life. Chemaphor is advancing NHE product
candidates for the food animal market, companion animal market and various,
potential human applications. More information can be found at
www.chemaphor.com.


Forward Looking Statements

This press release contains forward-looking statements regarding, among other
things, Chemaphor's beliefs, plans, objectives, strategies, estimates,
intentions and expectations. Actual results and events may differ materially
from those included in, contemplated or implied by such forward looking
statements for a variety of reasons. When used in this press release, the words
"seek", "believe", "develop", "intends", "will", "may", "potential", "should"
and similar expressions are intended to be among the statements that identify
forward-looking statements. Forward-looking statements are subject to inherent
risks and uncertainties including, but not limited to, market and general
economic conditions, the availability to attract and retain key personnel, the
availability and terms of financing, the scientific and commercial viability of
planned products, changes in Chemaphor's relationship with its key suppliers and
partners, competitive factors, changes in regulatory environments affecting
Chemaphor's business, and the accuracy in management's assumptions. This list is
not exhaustive of the factors that may affect any of Chemaphor's forward-looking
statements. Investors and others should carefully consider these and other
factors and not place undue reliance on these forward-looking statements. In
addition, these forward-looking statements relate to the date on which they were
made and Chemaphor disclaims and has no intention or obligation to update or
revise any forward-looking statement, whether as a result of new information,
future events or otherwise.

Chemaphor Inc. (TSXV:CFR)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024

Chemaphor Inc. (TSXV:CFR)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024